BD Announces CE Mark and US Market Launch New UltraTouch™ Push Button Blood Collection Set

BD Vacutainer® UltraTouch™ Push Button Blood Collection Set with Preattached Holder enhances offerings that protect healthcare workers from needlestick injury

FRANKLIN LAKES, N.J., June 16, 2020 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it obtained the CE mark in Europe for the BD Vacutainer® UltraTouch™ Push Button Blood Collection Set (BCS) with Preattached Holder. The product with preattached holder is being launched in the United States under the previously cleared BD Vacutainer® UltraTouch™ Push Button BCS.

The one-handed safety activation of the push button allows clinicians to activate the safety mechanism while still attending to the patient and venipuncture site. The preattached holder is designed to protect against accidental needlestick injury from the non-patient (tube-side) needle, and to help ensure OSHA single-use holder compliance. The wingset with pre-assembled holder is provided as one sterile unit.

“The preattached holder configurations of our UltraTouch™ BCS product portfolio are designed to address customers’ needs for improved sample quality, and overall efficiency and safety,” said Erik Allen, vice president and general manager, Specimen Management, BD. “Clinical evidence from multiple studies have shown that the BD Vacutainer® Push Button and UltraTouch family of blood collection sets provides the ability to access difficult veins with smaller gauge needles without sacrificing sample quality or tube fill time, and provides advanced safety against accidental needlestick injuries, compared to traditional wingsets.”

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

For more information on BD, please visit bd.com.

References


- BD Data on File (VS9248, VS9249, VS9250)


Contacts:
Gwen Gordon
BD Public Relations
858.617.2897
gwen.gordon@bd.com

Monique N. Dolecki
BD Investor Relations
201.847.5378
Monique_Dolecki@bd.com